We recently reported a better locoregional control (LRC) in locally advanced HNSCC treated by cisplatin-based chemoradiation than cetuximab-based bioradiotherapy, and a nonsignificant trend towards an improved OS [3] .
← all excerpts
Leukocytosis, prognosis biomarker in locally advanced head and neck cancer patients after chemoradiotherapy.
1
—
—